Pfizer
Stay current with all the latest and breaking news about Pfizer, compare headlines and perspectives between news sources on stories happening today. In total, 937 stories have been published about Pfizer which Ground News has aggregated in the past 3 months.Stay current with all the latest and breaking news about Pfizer, compare headlines and perspectives between news sources on stories happening today. In total, 937 stories have been published about Pfizer which Ground News has aggregated in the past 3 months.
Local News Publishers
No sources with tracked biases.
See less detail
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Pfizer News
Latest News Stories
US & Canada · New YorkThe ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer’s earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid, the company reported Tuesday.
The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion
56% Left coverage: 9 sources
US & Canada · WashingtonNew data from one U.S. Centers for Disease Control and Prevention (CDC) database shows a possible stroke risk link for older adults who received an updated Pfizer /BioNTech COVID-19 booster shot, but the signal is weaker than what the agency had flagged earlier in January, health officials said on Thursday.
U.S. CDC still looking at potential stroke risk from Pfizer bivalent COVID shot
Coverage: 7 sources
Business · New YorkJordan Walker, the Director of Research & Development Strategic Operations at Pfizer, was seen assaulting a journalist on camera. He was caught on camera saying that the pharma giant is working on mutating the Covid-19 virus strains for the development of new vaccines. Project Veritas, a conservative group known for undercover stories, had set up a date with the Pfizer Director.
Project Veritas Releases Video of Pfizer Exec Discussing 'Mutating' COVID-19 With 'Directed Evolution'
92% Right coverage: 37 sources
Business · New YorkU.S. drugmaker Pfizer Inc said on Tuesday it will offer its full portfolio of drugs, including off-patent medicines such as chemotherapies and oral cancer treatments, on a not-for-profit basis to 45 low-income countries in the world.
Pfizer to sell all its drugs in low-income countries at non-profit price
67% Center coverage: 9 sources
Google · New YorkPfizer is not in talks with Chinese authorities to license a generic version of its treatment Paxlovid for use there. Chief Executive Albert Bourla said the company is in discussions about a price for the branded product. China's Healthcare Security Administration (NHSA) said that the country would not include PaxlovID in an update to its list of medicines covered by basic medical insurance schemes.
Pfizer CEO says there will be no generic Paxlovid for China
50% Left coverage: 8 sources
Elon Musk · San FranciscoAn August 2021 email Dr. Scott Gottlieb, a former FDA commissioner and sitting board member of prominent COVID vaccine manufacturer Pfizer, sent to Twitter's senior public policy manager Todd O’Boyle flagged a tweet written by former Trump administration official Dr. Brett Giroir, who had written "It's now clear #COVID19 natural immunity is superior to #vaccine immunity, by ALOT. There's no scientific justification for #vax proof if a person had prior infection.," according to the latest Twitter Files.
Pfizer Board Member Pressured Twitter to Censor Posts on Natural Immunity, Low COVID Risk to Children: Emails
100% Right coverage: 9 sources
Asia · BeijingChina's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
Pfizer's Paxlovid not included in China's national insurance
48% Center coverage: 27 sources
PfizerPfizer's investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial. The trial involved adults males with a moderately severe to severe form of the disease. Pfizer plans to disclose additional key data from the study at a scientific conference in early 2023.
Pfizer's hemophilia B gene therapy succeeds in late-stage study
67% Center coverage: 6 sources
